Cefoxitin, a semisynthetic cephamycin antibiotic: in vivo evaluation.
Cefoxitin, 3-carbamoyloxymethyl-7-alpha-methoxy-7-[2-(2-thienyl)acetamido]-3-cephem-4- carboxylic acid, a semisynthetic cephamycin antibiotic shown to have broad-spectrum activity in vitro, is active also in vivo against a wide variety of bacteria including penicillin-resistant staphylococci. It is, however, particularly effective against gram-negative organisms including strains of indole-positive Proteus against which cephalothin and cephaloridine are ineffective. When cefoxitin is given subcutaneously, concentrations in mouse blood, urine, and other tissues are higher than those seen for cephalothin. Higher concentrations in the blood and greater therapeutic efficacy are achieved with cefoxitin when it is given with probenecid. For this reason it is believed that cefoxitin is excreted mainly by way of the renal tubules. The data indicate that cefoxitin has potential as a therapeutically useful antibiotic.
D000818:Animals; D001681:Biological Assay; D002219:Carbamates / Q000097:blood / Q000627:therapeutic use; D002511:Cephalosporins / Q000097:blood / Q000627:therapeutic use*; D004341:Drug Evaluation; D004756:Enterobacteriaceae Infections / Q000188:drug therapy*; D005260:Female; D008738:Methyl Ethers / Q000097:blood / Q000627:therapeutic use; D011339:Probenecid / Q000494:pharmacology
D002219:Carbamates; D002511:Cephalosporins; D008738:Methyl Ethers; D011339:Probenecid